Rani Therapeutics Holdings, Inc. Class A (RANI)

Over the past six months, Rani Therapeutics' stock price has experienced significant fluctuations. As of November 27, 2025, the stock was trading at $1.62, with a 52-week range between $0.39 and $3.87. The stock has seen a decrease of -16.06% over the last month and a -21.74% decrease over the last year as of October 17, 2025. Key events include a collaboration with Chugai Pharmaceutical, positive preclinical data for RT-114, an oversubscribed $60.3 million private placement agreement, earnings reports for Q1, Q2 and Q3 2025, and reports of insider selling.

There is no specific information indicating demand seasonality for Rani Therapeutics Holdings, Inc.'s products and services. Demand is primarily driven by the progress of clinical trials, regulatory approvals, and market adoption, rather than seasonal patterns. The company's revenue is currently low, with a trailing 12-month revenue of $1.2 million as of September 30, 2025.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on oral administration of biologics and drugs as an alternative to injections. Their core product is the RaniPill™ capsule, a platform technology designed to deliver various drug substances orally, with two configurations: RaniPill GO and RaniPill HC. The company's product pipeline includes RT-102 for osteoporosis, RT-105 for psoriatic arthritis, RT-110 for hypoparathyroidism, RT-111 for inflammatory conditions, RT-114 for obesity treatment (co-developed with ProGen Co., Ltd.), and RT-116 for obesity treatment.

Rani Therapeutics Holdings, Inc. is headquartered in San Jose, California, United States. The company has a collaboration deal with Chugai Pharmaceutical, a Japanese company, to leverage RaniPill technology for rare and immunological disorders with oral biologics.

Rani Therapeutics' brand reputation has been positively influenced by advancements in the RaniPill technology, the strategic partnership with Chugai Pharmaceutical, positive preclinical data for its obesity treatment pipeline, and the successful oversubscribed private placement agreement.

Rani Therapeutics Holdings has a mixed ownership structure, with approximately 3.32% owned by institutional shareholders, 33.62% by Rani Therapeutics insiders, and 63.06% by retail investors. Major institutional owners include Vanguard Group Inc., Nan Fung Group Holdings Ltd., and Citadel Advisors LLC. The largest individual shareholder is Mir A. Imran, who owns 24.89 million shares, representing 20.48% of the company.